GlassScriptPhysician profile
Ann Fontana
NPI 1437513025
$3,777.76
in general payments reported to CMS, 2019-2025
27 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $724 · 2022: $873 · 2023: $1,102 · 2024: $773 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,180.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,372.59 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $550.87 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $336.08 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $292.94 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $206.99 | 2021-2023 | |
| Amgen INC. | $173.41 | 2021-2024 | Otezla, Repatha |
| Amarin Pharma, INC. | $113.87 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $94.74 | 2021-2023 | |
| Abbott Laboratories | $93.86 | 2022-2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.42 | 2021 | |
| Dexcom, INC. | $71.65 | 2023-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $59.83 | 2021-2022 | |
| Pfizer INC. | $44.69 | 2025 | |
| Inspire Medical Systems, INC. | $43.57 | 2025 | Inspire |
| Exact Sciences Corporation | $34.88 | 2023-2025 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $22.69 | 2021 | |
| Xeris Pharmaceuticals, INC. | $21.16 | 2022 | |
| Paratek Pharmaceuticals, INC. | $19.97 | 2024 | Nuzyra |
| Astellas Pharma US INC | $19.75 | 2024 | Veozah |
| Boston Scientific Corporation | $19.44 | 2025 | Wavewriter Alpha Prime 16 |
| Idorsia Pharmaceuticals US INC | $18.06 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.97 | 2023 | Xifaxan |
| Dynavax Technologies Corporation | $15.63 | 2025 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $14.09 | 2024 | |
| Ethicon US, LLC | $13.02 | 2022 | |
| Antares Pharma, INC. | $12.33 | 2022 | |
| Eisai INC. | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Fontana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.